Journal: Journal of Cancer Research and Clinical Oncology

Article Title: DHRS9 promotes malignant progression of ovarian cancer through SQSTM1

doi: 10.1007/s00432-025-06290-y

Figure Lengend Snippet: DHRS9 expression levels correlate with overall survival in ovarian cancer patients. Kaplan–Meier curves were constructed from GEPIA ( a ) and KMplot ( b ) databases. Patients with higher DHRS9 expression exhibited reduced survival times relative to those with lower expression

Article Snippet: siRNAs targeting DHRS9 and SQSTM1 were synthesized by JTSBIO Co., Ltd. (China) and Sangon Biotech (China), respectively.

Techniques: Expressing, Construct

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: DHRS9 promotes malignant progression of ovarian cancer through SQSTM1

doi: 10.1007/s00432-025-06290-y

Figure Lengend Snippet: Effects of DHRS9 knockdown on aggressive phenotypes and apoptosis of A2780 cells. a , b qRT-PCR and western blot evaluating mRNA and protein expression of DHRS9 in IOSE-80, A2780 and OVCAR-3 cell lines. c , d qRT-PCR and western blot verification of DHRS9 knockdown efficiency. e , f CCK-8 and colony formation assays examining the effects of DHRS9 depletion on A2780 cell growth. g , h Transwell assays assessing the impact of DHRS9 knockdown on A2780 cell migration and invasion capabilities. i Flow cytometry-based apoptosis detection in DHRS9-silencing A2780 cells.Data are shown as mean ± SD. Scale bar = 200 μm. ** P < 0.01; *** P < 0.001;**** P < 0.0001

Article Snippet: siRNAs targeting DHRS9 and SQSTM1 were synthesized by JTSBIO Co., Ltd. (China) and Sangon Biotech (China), respectively.

Techniques: Knockdown, Quantitative RT-PCR, Western Blot, Expressing, CCK-8 Assay, Migration, Flow Cytometry

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: DHRS9 promotes malignant progression of ovarian cancer through SQSTM1

doi: 10.1007/s00432-025-06290-y

Figure Lengend Snippet: Effects of DHRS9 overexpression on aggressive phenotypes and apoptosis of OVCAR-3 cells. a , b qRT-PCR and western blot analysis verification of DHRS9 overexpression efficiency. c , d CCK-8 and colony formation assays examining the effects of DHRS9 overexpression on OVCAR-3 cell growth. e , f Transwell assays assessing the impact of DHRS9 overexpression on OVCAR-3 cell migration and invasion capabilities. g Analysis of apoptosis via flow cytometry in DHRS9-overexpressing OVCAR-3 cells. Data are shown as mean ± SD. Scale bar = 200 μm. ** P < 0.01; *** P < 0.001;**** P < 0.0001

Article Snippet: siRNAs targeting DHRS9 and SQSTM1 were synthesized by JTSBIO Co., Ltd. (China) and Sangon Biotech (China), respectively.

Techniques: Over Expression, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Migration, Flow Cytometry

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: DHRS9 promotes malignant progression of ovarian cancer through SQSTM1

doi: 10.1007/s00432-025-06290-y

Figure Lengend Snippet: Interaction between DHRS9 and SQSTM1. a Co-IP verification of the direct interaction between DHRS9 and SQSTM1 proteins. b , c Western blot analysis of SQSTM1 protein expression following DHRS9 overexpression and knockdown. Data are shown as mean ± SD. * P < 0.05;*** P < 0.001;**** P < 0.0001

Article Snippet: siRNAs targeting DHRS9 and SQSTM1 were synthesized by JTSBIO Co., Ltd. (China) and Sangon Biotech (China), respectively.

Techniques: Co-Immunoprecipitation Assay, Western Blot, Expressing, Over Expression, Knockdown

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: DHRS9 promotes malignant progression of ovarian cancer through SQSTM1

doi: 10.1007/s00432-025-06290-y

Figure Lengend Snippet: In vivo DHRS9 knockdown suppresses tumor growth in a xenograft model. a Representative images of subcutaneous tumors from nude mice injected with A2780 cells. b Final tumor weights. c Tumor growth curves showing inhibition of tumor progression following DHRS9 knockdown. d , e Western blot analysis confirming decreased DHRS9 and SQSTM1 protein expression in tumor tissues from the treatment group. Data are shown as mean ± SD. ** P < 0.01; *** P < 0.001

Article Snippet: siRNAs targeting DHRS9 and SQSTM1 were synthesized by JTSBIO Co., Ltd. (China) and Sangon Biotech (China), respectively.

Techniques: In Vivo, Knockdown, Injection, Inhibition, Western Blot, Expressing